Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 84Gastrointestinal 17CNS 11Head & Neck 9Genitourinary 6Gynecologic 5Tumor-Agnostic 4Thoracic 4Sarcoma 1Endocrine 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Neoplasms 2Ovarian Neoplasms 1Esophageal Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Lapatinib × Genitourinary × Clear all
NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

University of Southern California

Phase 2 Terminated
15 enrolled 10 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00246753 2017-06-28

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
29 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00103194 2014-09-30

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
49 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00095667 2013-05-08

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled
Genitourinary

Prostatic Neoplasms

NCT01700010 2013-01-17

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡